Memantine binding to a superficial site on NMDA receptors contributes to partial trapping.
Although many nervous system disorders are associated with N-methyl-D-aspartate (NMDA) receptor overactivation, pharmacological inhibition of NMDA receptors has typically demonstrated limited clinical value due to debilitating psychotomimetic side-effects. Memantine, however, induces far fewer behavioural side-effects than other NMDA receptor channel blockers such as ketamine, and slows the progressive cognitive decline associated with Alzheimer's disease. Memantine and ketamine inhibit NMDA receptors with similar affinity and kinetics. A prominent mechanistic difference between memantine and ketamine is the degree to which they are 'trapped' within the closed channel of NMDA receptors following removal of agonist: ketamine becomes trapped in nearly all NMDA receptors to which it was bound before agonist removal, whereas some bound memantine molecules dissociate after agonist removal, a phenomenon called partial trapping. Here we investigated the mechanism underlying partial trapping of memantine by recombinant NR1/2A NMDA receptors. We found that memantine dissociation from NR1/2A receptors after agonist removal (the process that results in partial trapping) followed an exponential time course with tau = 0.79 +/- 0.32 s. Neither membrane voltage depolarization nor maintained presence of memantine after agonist removal affected partial trapping, suggesting that partial trapping does not result from memantine escape through open channels. We tested the hypothesis that partial trapping results from binding of memantine to two sites, a superficial 'non-trapping' site and a deep 'trapping' site, which cannot be occupied simultaneously. This hypothesis was supported by the lack of ketamine binding to the superficial site, the voltage dependence of partial trapping, and the effect on partial trapping of a mutation near the deep site. The superficial binding site for memantine may, by causing partial trapping, contribute to memantine's unique therapeutic utility.
Kotermanski
Shawn E
SE
Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Wood
Jesse T
JT
Johnson
Jon W
JW
D019943:Amino Acid Substitution; D001665:Binding Sites / Q000235:genetics; D001667:Binding, Competitive; D002460:Cell Line; D018691:Excitatory Amino Acid Antagonists / Q000378:metabolism* / Q000494:pharmacology*; D006801:Humans; D007649:Ketamine / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D008559:Memantine / Q000378:metabolism* / Q000494:pharmacology*; D008564:Membrane Potentials; D008959:Models, Neurological; D016297:Mutagenesis, Site-Directed; D018408:Patch-Clamp Techniques; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D014162:Transfection
D018691:Excitatory Amino Acid Antagonists; D007649:Ketamine; D008559:Memantine; D016194:Receptors, N-Methyl-D-Aspartate; D011994:Recombinant Proteins; C409466:NR1 NMDA receptor
Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33
12955285
Curr Opin Pharmacol. 2003 Feb;3(1):101-9
12550750
J Neurophysiol. 1997 Jan;77(1):309-23
9120573
J Physiol. 1997 Feb 15;499 ( Pt 1):27-46
9061638
J Pharmacol Exp Ther. 2005 Sep;314(3):961-71
15901795
J Physiol. 1998 Jan 1;506 ( Pt 1):13-32
9481670
Neuron. 2002 Jan 3;33(1):75-85
11779481
J Pharmacol Exp Ther. 1999 Jan;288(1):204-10
9862772
Biophys J. 1998 Mar;74(3):1305-19
9512028
Curr Opin Pharmacol. 2006 Feb;6(1):61-7
16368266
Neuropharmacology. 1995 Oct;34(10):1239-58
8570022
Mol Pharmacol. 2002 Mar;61(3):533-45
11854433
Pharmacol Rev. 1999 Mar;51(1):7-61
10049997
Nature. 1993 Jan 7;361(6407):31-9
8421494
J Physiol. 1995 Mar 1;483 ( Pt 2):367-84
7650609
Eur J Neurosci. 1996 Mar;8(3):446-54
8963435
J Neurosci. 1992 Nov;12(11):4427-36
1432103
J Neurosci. 2009 Mar 4;29(9):2774-9
19261873
Neuropharmacology. 2007 Nov;53(6):699-723
17904591
J Neurochem. 2003 Oct;87(1):56-65
12969252
Science. 1992 Sep 4;257(5075):1415-9
1382314
J Pharmacol Exp Ther. 2001 Jun;297(3):906-14
11356910
J Physiol. 1998 Oct 1;512 ( Pt 1):47-60
9729616
J Physiol. 1996 Mar 15;491 ( Pt 3):779-97
8815211
Neuropharmacology. 1993 Dec;32(12):1337-50
8152525
J Neurosci. 1996 Jun 1;16(11):3549-58
8642401
Trends Neurosci. 2003 Feb;26(2):81-9
12536131